The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  The Oncologist

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1634/THEONCOLOGIST.8-4-307PMID 12897328
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.

  2009cited by this paper
• Prognostic significance of serum c-erbB-2 protein in breast cancer patients

  2005cited by this paper
• FISH detection of HER-2/neu oncogene amplification in early onset breast cancer

  2005cited by this paper
• Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

  2003cited by this paper
• Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.

  2003cited by this paper
• Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.

  2003cited by this paper
• Current Perspectives on HER2 Testing: A Review of National Testing Guidelines

  2003cited by this paper
• Male Breast Carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with Treatment and Survival, a Study of 65 Cases

  2002cited by this paper
• A testing algorithm for determination of HER2 status in patients with breast cancer.

  2002cited by this paper
• Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.

  2002cited by this paper
• Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

  2002cited by this paper
• Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.

  2002cited by this paper
• Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

  2002cited by this paper
• HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

  2002cited by this paper
• Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.

  2002cited by this paper
• Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer

  2002cited by this paper
• Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.

  2002cited by this paper
• Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

  2002cited by this paper
• Smart drugs: tyrosine kinase inhibitors in cancer therapy.

  2002cited by this paper
• Trastuzumab/chemotherapy combinations in metastatic breast cancer.

  2002cited by this paper
• C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.

  2002cited by this paper
• Prognostic value of c‐erbB2 expression in breast cancer

  2002cited by this paper
• Comparison of HER-2/ neu Oncogene Amplification Detected by Fluorescence In Situ Hybridization in Lobular and Ductal Breast Cancer

  2002cited by this paper
• Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries.

  2002cited by this paper
• Prediction of Response to Hormonal Treatment in Metastatic Breast Cancer

  2002cited by this paper
• The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).

  2002cited by this paper
• HER2 testing and correlation with efficacy of trastuzumab therapy.

  2002cited by this paper
• Clinical Relevance of Soluble c-erbB-2 for Patients with Metastatic Breast Cancer Predicting the Response to Second-Line Hormone or Chemotherapy

  2002cited by this paper
• HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.

  2002cited by this paper
• Assessment of HER-2/neu Status in Breast Cancer Automated Cellular Imaging System (ACIS)-Assisted Quantitation of Immunohistochemical Assay Achieves High Accuracy in Comparison With Fluorescence In Situ Hybridization Assay as the Standard

  2002cited by this paper
• Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.

  2002cited by this paper
• Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.

  2002cited by this paper
• Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma

  2002cited by this paper
• HER2 testing and correlation with efficacy of trastuzumab therapy.

  2002cited by this paper
• Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.

  2002cited by this paper
• Prognostic and predictive value of HER2/neu oncogene in breast cancer

  2002cited by this paper
• c-erbB-2 in breast cancer: development of a clinically useful marker.

  2002cited by this paper
• The HER2 extracellular domain as a prognostic and predictive factor in breast cancer.

  2002cited by this paper
• Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

  2002cited by this paper
• Amplification of Her-2/neu Gene in Her-2/neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material

  2002cited by this paper
• EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival

  2002cited by this paper
• Status of HER-2 in male and female breast carcinoma.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Role of adjuvant endocrine therapy in early-stage breast cancer.

  2001cited by this paper
• Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.

  2001cited by this paper
• Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

  2001cited by this paper
• The Predictive Value of HER2 in Breast Cancer

  2001cited by this paper
• HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support

  2001cited by this paper
• Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53

  2001cited by this paper
• c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease.

  2001cited by this paper
• Current status of HER2 testing: caught between a rock and a hard place.

  2001cited by this paper
• Biology of HER2 and Its Importance in Breast Cancer

  2001cited by this paper
• HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.

  2001cited by this paper
• Engineered antibodies take center stage

  2001cited by this paper
• Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.

  2001cited by this paper
• Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

  2001cited by this paper
• Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.

  2001cited by this paper
• Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.

  2001cited by this paper
• C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.

  2001cited by this paper
• Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy.

  2001cited by this paper
• Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

  2001cited by this paper
• Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard.

  2001cited by this paper
• Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.

  2001cited by this paper
• Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.

  2001cited by this paper
• Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.

  2001cited by this paper
• c‐erbB‐2 (HER‐2/neu) gene amplification is a better indicator of poor prognosis than protein over‐expression in operable breast‐cancer patients

  2001cited by this paper
• The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis

  2001cited by this paper
• Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.

  2001cited by this paper
• Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.

  2001cited by this paper
• Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.

  2001cited by this paper
• Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.

  2001cited by this paper
• Molecular markers in Paget disease of the breast

  2001cited by this paper
• Evaluation of HER-2/neu in Serum and Tissue of Primary and Metastatic Breast Cancer Patients using an Automated Enzyme Immunoassay

  2001cited by this paper
• Co‐expression of epidermal growth factor receptor and transforming growth factor‐α predicts worse prognosis in breast‐cancer patients

  2000cited by this paper
• Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

  2000cited by this paper
• Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study

  2000cited by this paper
• Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.

  2000cited by this paper
• Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.

  2000cited by this paper
• The association of HER-2/neu amplification with breast cancer recurrence.

  2000cited by this paper
• Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.

  2000cited by this paper
• Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.

  2000cited by this paper
• Angiogenesis, p53, and c‐erbB‐2 immunoreactivity and clinicopathological features in male breast cancer

  2000cited by this paper
• Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.

  2000cited by this paper
• C-erbB-2 overexpression and survival in early onset breast cancer

  2000cited by this paper
• HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer.

  2000cited by this paper
• Topoisomerase IIα Expression in Breast Cancer: Correlation with Outcome Variables

  2000cited by this paper
• A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer.

  2000cited by this paper
• Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.

  2000cited by this paper
• The prognostic value of p53 and c‐erb b‐2 immunostaining is overrated for patients with lymph node negative breast carcinoma

  2000cited by this paper
• Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.

  2000cited by this paper
• Comparison of the metastasis‐inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer

  2000cited by this paper
• Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study.

  2000cited by this paper
• Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

  2000cited by this paper
• HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With Survival

  2000cited by this paper
• A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.

  2000cited by this paper
• Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.

  2000cited by this paper

• Correlation between HER2 gene copy number and immunohistochemistry categories in HER2-negative breast cancer: diagnostic utility for differentiating HER2-null, ultralow, and low tumors.

  2026cites this paper
• Successful use of trastuzumab deruxtecan in hepatic visceral crisis secondary to metastatic HER2-low breast cancer

  2025cites this paper
• Plasma-derived exosomal human epidermal growth factor receptor 2 (HER2) protein for distinguishing breast cancer from benign breast disease and assessing the efficacy of neoadjuvant therapy

  2025cites this paper
• Electrochemical aptasensing of HER2 breast cancer biomarker using a Ni nanofoam/Ag–Au ternary nanocomposite

  2025cites this paper
• GRAPE: graph-regularized protein language modeling unlocks TCR-epitope binding specificity

  2025cites this paper
• Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future

  2025cites this paper
• Comparison of Immunohistochemical 2 (+) HER2 Gene Status with SISH in Invasive Breast Carcinoma

  2025cites this paper
• Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision

  2025cites this paper
• CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression

  2025cites this paper
• Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study.

  2025cites this paper
• Artificial intelligence in determining the molecular biological subtype of breast cancer

  2025cites this paper
• Novel computer-aided systems for interpreting immu- nohistochemistry (IHC) results in breast cancer based on deep learning algorithms: A systematic review

  2025cites this paper
• Highly Sensitive Detection and Molecular Subtyping of Breast Cancer Cells Using Machine Learning-assisted SERS Technology

  2025cites this paper
• A Comparison Between Immunohistochemistry and mRNA Expression to Identify Human Epidermal Growth Factor Receptor 2-Low Breast Cancer.

  2024cites this paper
• Evaluation of the Efficacy of Postoperative Adjuvant Therapy for HER2-Positive Ductal Carcinoma in Situ with Microinvasion

  2024cites this paper
• Comparing the Sensitivity of HER2 Epitope Detection of HercepTest mAb pharmDx (Dako Omnis, GE001) and Ventana PATHWAY Anti-HER-2/neu (4B5) Using IHC Calibrators

  2024cites this paper
• Computational insights into overcoming resistance mechanisms in targeted therapies for advanced breast cancer: focus on EGFR and HER2 co-inhibition

  2024cites this paper
• Development and validation of a radiomics-based nomogram for predicting two subtypes of HER2-negative breast cancer

  2024cites this paper
• Unlocking the potential of oncology biomarkers: advancements in clinical theranostics

  2024cites this paper
• De-Escalating Treatment Strategies for Patients with Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Early-Stage Breast Cancer

  2024cites this paper
• GTE: a graph learning framework for prediction of T-cell receptors and epitopes binding specificity

  2024cites this paper
• ERα, HER-2, pan-RAS, p53, and aromatase expression in spontaneous malignant canine mammary tumors: Prognostic relevance and association with clinicohistological parameters.

  2024cites this paper
• Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer

  2024cites this paper
• Combined, yet separate: cocktails of carriers (not drugs) for actinium-225 α-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers

  2024cites this paper
• Breast Cancer Screening Using Artificial Intelligence Techniques: Enhancing Biochemical Insights and Diagnostic Accuracy

  2023cites this paper
• Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort.

  2023cites this paper
• Особливості перебігу раку грудної залози з низьким рівнем експресії HER2/neu

  2023cites this paper
• Potential diagnostic and prognostic biomarkers for breast cancer: A compiled review.

  2023cites this paper
• Emerging Landscape of Targeted Therapy of Breast Cancers With Low HER2 Protein Expression.

  2023cites this paper
• Loss of Human Epidermal Receptor 2 Expression in Formalin-Fixed Paraffin-Embedded Breast Cancer Samples and the Rescuing Effect of Enhanced Antigen Retrieval and Signal Amplification

  2023cites this paper
• Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study

  2023cites this paper
• Combined, yet Separate: cocktails of carriers (not drugs) for α-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers

  2023cites this paper
• Multicentricity in Different Molecular Subtypes of Breast Cancer: A Cross-sectional Study in Isfahan

  2023cites this paper
• Aptamer: A Theranostic Approach Towards Breast Cancer

  2023cites this paper
• High-multiplex tissue imaging in routine pathology—are we there yet?

  2023cites this paper
• The Significance of Recognition of Human Epidermal Growth Factor 2 Low in Breast Cancer Therapy

  2023cites this paper
• Electro-plasmonic-assisted biosensing of proteins and cells at the surface of optical fiber.

  2022cites this paper
• Spatial-Division Multiplexing Approach for Simultaneous Detection of Fiber-Optic Ball Resonator Sensors: Applications for Refractometers and Biosensors

  2022cites this paper
• Novel lncRNAs with diagnostic or prognostic value screened out from breast cancer via bioinformatics analyses

  2022cites this paper
• Cost-Effective Fiber Optic Solutions for Biosensing

  2022cites this paper
• Electrochemical plasmonic optical fiber grating sensor for cancer biomarker detection

  2022cites this paper
• Novel markers in breast pathology

  2022cites this paper
• Construction and Validation of a 15-Top-prognostic-gene-based Signature to Indicate the Dichotomized Clinical Outcome and Response to Targeted Therapy for Bladder Cancer Patients

  2022cites this paper
• The force of cell-cell adhesion in determining the outcome in a nonlocal advection diffusion model of wound healing.

  2022cites this paper
• HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles

  2022cites this paper
• Prophylactic Mastectomy, BCT, And Axillary Lymph Node Removal

  2022cites this paper
• Her2low breast cancer. New opportunities and challenges

  2022cites this paper
• Durable effect of pyrotinib plus capecitabine in HER-2+ breast cancer patient undergoing peritoneal dialysis: A case report and literature review

  2022cites this paper
• Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer

  2022cites this paper
• A highly specific and flexible detection assay using collaborated actions of DNA-processing enzymes for identifying multiple gene expression signatures in breast cancer.

  2022cites this paper
• Ultralow Limit Detection of Soluble HER2 Biomarker in Serum with a Fiber-Optic Ball-Tip Resonator Assisted by a Tilted FBG

  2022cites this paper
• A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer

  2022cites this paper
• HER2-Low Breast Cancers New Opportunities and challenges

  2021influential citation
• The Prognostic Impact of HER2 Genetic and Protein Expression in Pancreatic Carcinoma—HER2 Protein and Gene in Pancreatic Cancer

  2021cites this paper
• HER2-Positive (HER2 +) Breast Cancer

  2021cites this paper
• The Exciting New Field of HER2-Low Breast Cancer Treatment

  2021cites this paper
• Significance of HER2 in Microinvasive Breast Carcinoma.

  2021cites this paper
• Movement of Mitochondria with Mutant DNA through Extracellular Vesicles Helps Cancer Cells Acquire Chemoresistance

  2021cites this paper
• Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer

  2021cites this paper
• Two diverse carriers are better than one: A case study in α‐particle therapy for prostate specific membrane antigen‐expressing prostate cancers

  2021cites this paper
• Eugenol-Induced Autophagy and Apoptosis in Breast Cancer Cells via PI3K/AKT/FOXO3a Pathway Inhibition

  2021cites this paper
• HER2-Low Breast Cancers.

  2021cites this paper
• Cell-penetrating peptides in cancer targeting

  2021cites this paper
• Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV

  2021cites this paper
• Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

  2021cites this paper
• HER2 breast cancer biomarker detection using a sandwich optical fiber assay.

  2021cites this paper
• Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is downregulated in Invasive ductal carcinoma and potential prognostic marker of breast cancer

  2021cites this paper
• Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin)

  2021cites this paper
• Bispecific Antibodies for IFN-β Delivery to ErbB2+ Tumors

  2021cites this paper
• Breast-to-brain metastasis: a focus on the pre-metastatic niche

  2021cites this paper
• Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer

  2021cites this paper
• Analysis of absorbed dose in radioimmunotherapy with 177Lu-trastuzumab using two different imaging scenarios: a pilot study

  2021cites this paper
• Biomarkers

  2020cites this paper
• Prognostic Significance of HER-2 Expression in Gastric Cancer

  2020cites this paper
• Identification of ZG16B as a prognostic biomarker in breast cancer

  2020cites this paper
• A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy

  2020cites this paper
• HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes

  2020cites this paper
• HER2 biosensing through SPR-envelope tracking in plasmonic optical fiber gratings.

  2020cites this paper
• OVEREXPRESSION of HER2/neu GENE: CORRELATION WITH HISTOLOGICAL GRADING IN BREAST CARCINOMA

  2020cites this paper
• Comparative Analysis of the Development of Acquired Radioresistance in Canine and Human Mammary Cancer Cell Lines

  2020cites this paper
• Recombinant Bispecific Antibodies to the Human ErbB2 Receptor and Interferon-Beta

  2020cites this paper
• Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer

  2020cites this paper
• Applying the New Guidelines of HER2 Testing in Breast Cancer

  2020cites this paper
• MRI and the pathology of breast invasive micropapillary carcinoma

  2020cites this paper
• THE SIGNIFICANCE OF CEA AND CA15-3 IN EARLY BREAST CANCER ITS ASSOCIATION WITH CLINICO PATHOLOGICAL CHARACTERISTICS A SINGLE-CENTER STUDY IN MADINAH, SAUDI ARABIA

  2020cites this paper
• Exosomes in Triple Negative Breast Cancer: Garbage Disposals or Trojan Horses?

  2020cites this paper
• Polymeric nanoassemblies for enrichment and detection of peptides and proteins in human breast milk

  2020cites this paper
• HER2 biosensing through SPR-envelope tracking in plasmonic optical fiber gratings

  2020cites this paper
• Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer

  2020cites this paper
• A Comparative Analysis of Body Mass Index with Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Pre- and Postmenopausal Breast Cancer Patients

  2020cites this paper
• A system biology study of the molecular mechanism of Metformin on breast cancer

  2019cites this paper
• Profiling of 54 plasma glycoproteins by label-free targeted LC-MS/MS.

  2019cites this paper
• RELATIONSHIP AMONG EXPRESSION OF E-CADHERIN AND HER-2/NEU WITH METASTASIS IN BREAST CANCER

  2019cites this paper
• Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma.

  2019cites this paper
• A SIGNATURE ENRICHMENT DESIGN WITH BAYESIAN ADAPTIVE RANDOMIZATION FOR CANCER CLINICAL TRIALS

  2019cites this paper
• Recognition Sites for Cancer-Targeting Durg Delivery Systems.

  2019cites this paper
• Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

  2019cites this paper
• Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden

  2019cites this paper
• Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort

  2019cites this paper
• VEGF family factors and their receptors in the diagnostics of breast cancer

  2019cites this paper